FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:861-869 September 20, 2001 Number 12 Next

	Full Text PDF Editorial by Hostetter, T. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin–angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II–receptor antagonist losartan in patients with type 2 diabetes and nephropathy.

Methods A total of 1513 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once daily) with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally acting agents), for a mean of 3.4 years. The primary outcome was the composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Secondary end points included a composite of morbidity and mortality from cardiovascular causes, proteinuria, and the rate of progression of renal disease.

Results A total of 327 patients in the losartan group reached the primary end point, as compared with 359 in the placebo group (risk reduction, 16 percent; P=0.02). Losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction, 25 percent; P=0.006) and end-stage renal disease (risk reduction, 28 percent; P=0.002) but had no effect on the rate of death. The benefit exceeded that attributable to changes in blood pressure. The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalization for heart failure was significantly lower with losartan (risk reduction, 32 percent; P=0.005). The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo).

Conclusions Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.

Source Information

From the Renal Division, Brigham and Women's Hospital, Boston (B.M.B.); the Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia (M.E.C.); the Department of Clinical Pharmacology, University of Groningen, Groningen, the Netherlands (D.Z.); the Department of Medicine, Hennepin County Medical Center, Minneapolis (W.F.K.); the Renal Division, Emory University, Atlanta (W.E.M.); Steno Diabetes Center, Gentofte, Denmark (H.-H.P.); Laboratori Negri Bergamo, Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy (G.R.); and Merck Research Laboratories, Blue Bell, Pa. (S.M.S., Z.Z., S.S.).

Address reprint requests to Dr. Brenner at the Renal Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at bbrenner{at}partners.org.

Full Text of this Article

This article has been cited by other articles:

• Teo, K. K. (2009). Clinical evidence from ONTARGET: proven cardio- and vascular protection. Eur Heart J Suppl 11: F9-F15 [Abstract] [Full Text]  
• Unger, T. (2009). The rationale for choosing telmisartan and ramipril in the ONTARGET programme. Eur Heart J Suppl 11: F3-F8 [Abstract] [Full Text]  
• Dobre, D., Lambers Heerspink, H. J., de Zeeuw, D. (2009). Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 11: F39-F46 [Abstract] [Full Text]  
• Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J.V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., the TREAT Investigators, (2009). A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. NEJM 361: 2019-2032 [Abstract] [Full Text]  
• Ishizawa, K., Izawa-Ishizawa, Y., Dorjsuren, N., Miki, E., Kihira, Y., Ikeda, Y., Hamano, S., Kawazoe, K., Minakuchi, K., Tomita, S., Tsuchiya, K., Tamaki, T. (2009). Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner. Nephrol Dial Transplant 0: gfp520v2-gfp520 [Abstract] [Full Text]  
• Philipp, T., Martinez, F., Geiger, H., Moulin, B., Mourad, G., Schmieder, R., Lievre, M., Heemann, U., Legendre, C. (2009). Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 0: gfp581v1-gfp581 [Abstract] [Full Text]  
• Ravid, M. (2009). Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy. Diabetes Care 32: S410-S413 [Full Text]  
• Gagliardini, E., Corna, D., Zoja, C., Sangalli, F., Carrara, F., Rossi, M., Conti, S., Rottoli, D., Longaretti, L., Remuzzi, A., Remuzzi, G., Benigni, A. (2009). Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am. J. Physiol. Renal Physiol. 297: F1448-F1456 [Abstract] [Full Text]  
• Messerli, F. H., Bangalore, S., Ruschitzka, F. (2009). Angiotensin receptor blockers: baseline therapy in hypertension?. Eur Heart J 30: 2427-2430 [Full Text]  
• Postma, M. J., de Zeeuw, D. (2009). The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant 24: 2975-2983 [Full Text]  
• Jain, G., Campbell, R. C., Warnock, D. G. (2009). Mineralocorticoid Receptor Blockers and Chronic Kidney Disease. CJASN 4: 1685-1691 [Abstract] [Full Text]  
• Delea, T. E., Sofrygin, O., Palmer, J. L., Lau, H., Munk, V. C., Sung, J., Charney, A., Parving, H.-H., Sullivan, S. D. (2009). Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria. J. Am. Soc. Nephrol. 20: 2205-2213 [Abstract] [Full Text]  
• Akbari, A., Knoll, G., Ferguson, D., McCormick, B., Davis, A., Biyani, M. (2009). ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PERITONEAL DIALYSIS: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. pdi 29: 554-561 [Abstract] [Full Text]  
• Sugiura, T., Wada, A. (2009). Resistive index predicts renal prognosis in chronic kidney disease. Nephrol Dial Transplant 24: 2780-2785 [Abstract] [Full Text]  
• Redon, J., Fabia, M. J. (2009). Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. Journal of Renin-Angiotensin-Aldosterone System 10: 147-156 [Abstract]  
• Zhang, Y., Deb, D. K., Kong, J., Ning, G., Wang, Y., Li, G., Chen, Y., Zhang, Z., Strugnell, S., Sabbagh, Y., Arbeeny, C., Li, Y. C. (2009). Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am. J. Physiol. Renal Physiol. 297: F791-F801 [Abstract] [Full Text]  
• Ruggenenti, P., Cattaneo, D., Loriga, G., Ledda, F., Motterlini, N., Gherardi, G., Orisio, S., Remuzzi, G. (2009). Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk: Effects of Acetyl-L-Carnitine Therapy. Hypertension 54: 567-574 [Abstract] [Full Text]  
• Konoshita, T., Kato, N., Fuchs, S., Mizuno, S., Aoyama, C., Motomura, M., Makino, Y., Wakahara, S., Inoki, I., Miyamori, I., Pinet, F., for the Genomic Disease Outcome Consortium (G-DOC), (2009). Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers. Diabetes Care 32: 1485-1490 [Abstract] [Full Text]  
• Lash, J. P., Go, A. S., Appel, L. J., He, J., Ojo, A., Rahman, M., Townsend, R. R., Xie, D., Cifelli, D., Cohan, J., Fink, J. C., Fischer, M. J., Gadegbeku, C., Hamm, L. L., Kusek, J. W., Landis, J. R., Narva, A., Robinson, N., Teal, V., Feldman, H. I., the Chronic Renal Insufficiency Cohort (CRIC) Stud, (2009). Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline Characteristics and Associations with Kidney Function. CJASN 4: 1302-1311 [Abstract] [Full Text]  
• Cohen, D. L., Townsend, R. R. (2009). Is There Added Value to Adding ARB to ACE Inhibitors in the Management of CKD?. J. Am. Soc. Nephrol. 20: 1666-1668 [Abstract] [Full Text]  
• RamachandraRao, S. P., Zhu, Y., Ravasi, T., McGowan, T. A., Toh, I., Dunn, S. R., Okada, S., Shaw, M. A., Sharma, K. (2009). Pirfenidone Is Renoprotective in Diabetic Kidney Disease. J. Am. Soc. Nephrol. 20: 1765-1775 [Abstract] [Full Text]  
• Parving, H.-H., Brenner, B. M., McMurray, J. J.V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Pfeffer, M. A. (2009). Dual Renin-Angiotensin system blockade and kidney disease.. J Am Coll Cardiol 54: 278-279 [Full Text]  
• Mann, J. F.E., Schmieder, R. E., Dyal, L., McQueen, M. J., Schumacher, H., Pogue, J., Wang, X., Probstfield, J. L., Avezum, A., Cardona-Munoz, E., Dagenais, G. R., Diaz, R., Fodor, G., Maillon, J. M., Ryden, L., Yu, C. M., Teo, K. K., Yusuf, S., for the TRANSCEND (Telmisartan Randomised Assessme, (2009). Effect of Telmisartan on Renal Outcomes: A Randomized Trial. ANN INTERN MED 151: 1-10 [Abstract] [Full Text]  
• Bilous, R., Chaturvedi, N., Sjolie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., Parving, H.-H. (2009). Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes: Three Randomized Trials. ANN INTERN MED 151: 11-20 [Abstract] [Full Text]  
• Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., Klein, R. (2009). Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. NEJM 361: 40-51 [Abstract] [Full Text]  
• On behalf of the Canadian Hypertension Education P, (2009). 2009 Canadian Hypertension Education Program recommendations: An annual update. cfp 55: 697-700 [Full Text]  
• Schiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S., Sorensen, S. A., Wilcox, W. R., Desnick, R. J. (2009). Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24: 2102-2111 [Abstract] [Full Text]  
• Sever, P. S, Gradman, A. H, Azizi, M. (2009). Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of Renin-Angiotensin-Aldosterone System 10: 65-76 [Abstract]  
• Nikzamir, A., Esteghamati, A., Feghhi, M., Nakhjavani, M., Rashidi, A., Javad Zavar Reza, (2009). The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes. Journal of Renin-Angiotensin-Aldosterone System 10: 109-114 [Abstract]  
• Guo, L. L., Pan, Y., Jin, H. M. (2009). Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 24: 1876-1883 [Abstract] [Full Text]  
• Elijovich, F., Laffer, C. (2009). A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 3: 231-240 [Abstract]  
• O'Hare, A. M., Kaufman, J. S., Covinsky, K. E., Landefeld, C. S., McFarland, L. V., Larson, E. B. (2009). Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?. ANN INTERN MED 150: 717-724 [Abstract] [Full Text]  
• Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671 [Abstract] [Full Text]  
• Oudit, G. Y., Imai, Y., Kuba, K., Scholey, J. W., Penninger, J. M. (2009). The role of ACE2 in pulmonary diseases--relevance for the nephrologist. Nephrol Dial Transplant 24: 1362-1365 [Full Text]  
• West, M., Nicholls, K., Mehta, A., Clarke, J. T.R., Steiner, R., Beck, M., Barshop, B. A., Rhead, W., Mensah, R., Ries, M., Schiffmann, R. (2009). Agalsidase Alfa and Kidney Dysfunction in Fabry Disease. J. Am. Soc. Nephrol. 20: 1132-1139 [Abstract] [Full Text]  
• Vargas, S. L., Toma, I., Kang, J. J., Meer, E. J., Peti-Peterdi, J. (2009). Activation of the Succinate Receptor GPR91 in Macula Densa Cells Causes Renin Release. J. Am. Soc. Nephrol. 20: 1002-1011 [Abstract] [Full Text]  
• McInnes, G. T. (2009). Telmisartan to Prevent Recurrent Stroke: The PRoFESS Study: Was the Baby Thrown Out With the Bathwater?. Stroke 40: 1938-1940 [Full Text]  
• Singh, P., Deng, A., Blantz, R. C., Thomson, S. C. (2009). Unexpected effect of angiotensin AT1 receptor blockade on tubuloglomerular feedback in early subtotal nephrectomy. Am. J. Physiol. Renal Physiol. 296: F1158-F1165 [Abstract] [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2009). Differences in Control of Cardiovascular Disease and Diabetes by Race, Ethnicity, and Education: U.S. Trends From 1999 to 2006 and Effects of Medicare Coverage. ANN INTERN MED 150: 505-515 [Abstract] [Full Text]  
• Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90 [Full Text]  
• 2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 [Full Text]  
• Cortinovis, M., Perico, N., Cattaneo, D., Remuzzi, G. (2009). Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis 3: 133-143 [Abstract]  
• Nuzum, D. S., Merz, T. (2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice 22: 135-148 [Abstract]  
• Dreyer, G., Hull, S., Aitken, Z., Chesser, A., Yaqoob, M.M. (2009). The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. QJM 102: 261-269 [Abstract] [Full Text]  
• Agarwal, R. (2009). Blood Pressure Components and the Risk for End-Stage Renal Disease and Death in Chronic Kidney Disease. CJASN 4: 830-837 [Abstract] [Full Text]  
• Burgess, E., Muirhead, N., de Cotret, P. R., Chiu, A., Pichette, V., Tobe, S., the SMART (Supra Maximal Atacand Renal Trial) Inve, (2009). Supramaximal Dose of Candesartan in Proteinuric Renal Disease. J. Am. Soc. Nephrol. 20: 893-900 [Abstract] [Full Text]  
• de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C.-E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancia, G., Woodward, M., Glasziou, P., Grobbee, D. E., MacMahon, S., Chalmers, J., on behalf of the ADVANCE Collaborative Group, (2009). Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. J. Am. Soc. Nephrol. 20: 883-892 [Abstract] [Full Text]  
• Fried, L. (2009). Are We Ready to Screen the General Population for Microalbuminuria?. J. Am. Soc. Nephrol. 20: 686-688 [Full Text]  
• Harita, Y., Kurihara, H., Kosako, H., Tezuka, T., Sekine, T., Igarashi, T., Ohsawa, I., Ohta, S., Hattori, S. (2009). Phosphorylation of Nephrin Triggers Ca2+ Signaling by Recruitment and Activation of Phospholipase C-{gamma}1. J. Biol. Chem. 284: 8951-8962 [Abstract] [Full Text]  
• Verdecchia, P., Angeli, F., Cavallini, C., Gattobigio, R., Gentile, G., Staessen, J. A., Reboldi, G. (2009). Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 30: 679-688 [Abstract] [Full Text]  
• Thilly, N., Boini, S., Kessler, M., Briancon, S., Frimat, L. (2009). Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale). Nephrol Dial Transplant 24: 934-939 [Abstract] [Full Text]  
• Onuigbo, M.A.C. (2009). Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection. QJM 102: 155-167 [Abstract] [Full Text]  
• Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., Strippoli, G. F.M. (2009). Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis. CJASN 4: 542-551 [Abstract] [Full Text]  
• Wenzel, R. R., Littke, T., Kuranoff, S., Jurgens, C., Bruck, H., Ritz, E., Philipp, T., Mitchell, A., for the SPP301 (Avosentan) Endothelin Antagonist E, (2009). Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria. J. Am. Soc. Nephrol. 20: 655-664 [Abstract] [Full Text]  
• Zhang, L., Du, J., Hu, Z., Han, G., Delafontaine, P., Garcia, G., Mitch, W. E. (2009). IL-6 and Serum Amyloid A Synergy Mediates Angiotensin II-Induced Muscle Wasting. J. Am. Soc. Nephrol. 20: 604-612 [Abstract] [Full Text]  
• Fried, L. F., Duckworth, W., Zhang, J. H., O'Connor, T., Brophy, M., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S., Warren, S. R., Peduzzi, P., for VA NEPHRON-D Investigators, (2009). Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). CJASN 4: 361-368 [Abstract] [Full Text]  
• Kolesnyk, I., Noordzij, M., Dekker, F. W., Boeschoten, E. W., Krediet, R. T. (2009). A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 24: 272-277 [Abstract] [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Kjeldsen, S. E., Aksnes, T. A., Fagard, R. H., Mancia, G. (2009). CHAPTER 13 Hypertension. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Cosentino, F., Rydén, L., Francia, P., Mellbin, L. G. (2009). CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Satoh, M., Fujimoto, S., Arakawa, S., Yada, T., Namikoshi, T., Haruna, Y., Horike, H., Sasaki, T., Kashihara, N. (2008). Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 23: 3806-3813 [Abstract] [Full Text]  
• Radbill, B., Murphy, B., LeRoith, D. (2008). Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clin Proc. 83: 1373-1381 [Abstract] [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Gao, S. MSc, Manns, B. J. MD MSc, Culleton, B. F. MD, Tonelli, M. MD SM, Quan, H. PhD, Crowshoe, L. MD, Ghali, W. A. MD MPH, Svenson, L. W. BSc, Ahmed, S. MD MMSc, Hemmelgarn, B. R. PhD MD, for the Alberta Kidney Disease Network, (2008). Access to health care among status Aboriginal people with chronic kidney disease. CMAJ 179: 1007-1012 [Abstract] [Full Text]  
• Wright, J., Vardhan, A. (2008). Review: The problem of diabetic nephropathy and practical prevention of its progression. British Journal of Diabetes & Vascular Disease 8: 272-277 [Abstract]  
• Turnbull, F., Woodward, M., Neal, B., Barzi, F., Ninomiya, T., Chalmers, J., Perkovic, V., Li, N., MacMahon, S., the Blood Pressure Lowering Treatment Trialists' C, (2008). Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 29: 2669-2680 [Abstract] [Full Text]  
• Abdel-Rahman, E. M., Abadir, P. M., Siragy, H. M. (2008). Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295: R1473-R1478 [Abstract] [Full Text]  
• Spurney, R. F., Coffman, T. M. (2008). Stressed-out Podocytes in Diabetes?. J. Am. Soc. Nephrol. 19: 2035-2037 [Full Text]  
• Cade, W T. (2008). Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. ptjournal 88: 1322-1335 [Abstract] [Full Text]  
• Zhang, Z., Zhang, Y., Ning, G., Deb, D. K., Kong, J., Li, Y. C. (2008). Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc. Natl. Acad. Sci. USA 105: 15896-15901 [Abstract] [Full Text]  
• HIRSCH, S. (2008). An update on proteinuric chronic kidney disease: The dual-goal approach. Cleveland Clinic Journal of Medicine 75: 705-713 [Abstract] [Full Text]  
• Galle, J., Schwedhelm, E., Pinnetti, S., Boger, R. H., Wanner, C., on behalf of the VIVALDI investigators, (2008). Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23: 3174-3183 [Abstract] [Full Text]  
• Peti-Peterdi, J., Kang, J. J., Toma, I. (2008). Activation of the renal renin-angiotensin system in diabetes--new concepts. Nephrol Dial Transplant 23: 3047-3049 [Full Text]  
• Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93: 3671-3689 [Abstract] [Full Text]  
• Izuhara, Y., Sada, T., Yanagisawa, H., Koike, H., Ohtomo, S., Dan, T., Ito, S., Nangaku, M., van Ypersele de Strihou, C., Miyata, T. (2008). A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats. Arterioscler. Thromb. Vasc. Bio. 28: 1767-1773 [Abstract] [Full Text]  
• Franks, A. M, O'Brien, C. E, Stowe, C. D, Wells, T. G, Gardner, S. F (2008). Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children. The Annals of Pharmacotherapy 42: 1388-1395 [Abstract] [Full Text]